Will an AI-Designed Drug Receive Regulatory Approval by 2030?

World's First End-To-End AI Drug Developer To Power Into Black On Lucrative Partnerships - Eli Lilly (NYS - Benzinga

Insilico Medicine flagged a strong interim profit surge in 2026 driven by licensing and collaboration deals worth over $7 billion (including a $2.75B Lilly R&D deal, a $2.5B SK Biopharmaceuticals pact, and a $600M Takeda collaboration), with 31 preclinical candidates and six programs in clinical development, while its AI-discovered Rentosertib began Phase 3 for idiopathic pulmonary fibrosis but pivotal results are not expected until late 2027, highlighting rapid near-term earnings potential alongside long development timelines and regulatory risks for AI-discovered drugs.

FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients

The FDA approved Lipfendra, Merck’s first-of-its-kind nonin injectable pill that, when added to statins, can reduce LDL cholesterol by about 55–59% in high-risk patients, with a six-month impact and manageable side effects, marking a major advance for those who don’t respond adequately to statins.

Kalshi Launches Bets on FDA Decisions and Clinical Trials Outcomes

Kalshi is launching prediction markets to bet on late-stage clinical trial outcomes and FDA regulatory decisions, in partnership with AppliedXL, with contracts based on public documents (e.g., ClinicalTrials.gov endpoints, FDA letters, or advisory committee votes), opened only after enrollment begins and with outcomes verified against official sources, allowing bets on individual drugs rather than entire companies while requiring employer verification and prohibiting trading by those with material nonpublic information.

Can Governance-by-Design Make AI Compliant in Pharma? (Part II) | Pharmaceutical Technology

A governance-first architecture for AI in pharma—centered on an applicability engine and authoritative, rules-based governing knowledge—can enable compliant, traceable changes by humans approving scope before automation, linking decisions to specific competencies, evidence, and training, and avoiding blanket retraining or uncontrolled autonomous decisions.

PYMNTS | Kalshi Launches Prediction Markets for Clinical Trials

Kalshi and AppliedXL launched a pilot prediction market program to trade on clinical trial outcomes and FDA regulatory decisions, providing publicly updated drug-development odds and resolution infrastructure to reconcile data from multiple sources, with insider-trading safeguards and a focus on trading individual drug milestones.

Patent expiries of $300-billion by 2030 offer India a chance to move beyond generics: NITI Aayog - Healthcare News | The Financial Express

NITI Aayog’s BioPharmaNext roadmap envisions India moving from generics to high-value biopharma by 2035, leveraging nearly $300 billion of global patent expiries by 2030, establishing an Rs 50,000-crore BioEconomy Growth Fund, AI-driven drug discovery, biosimilars, and five integrated bio-innovation clusters to accelerate regulatory approvals, reduce development time, and grow India’s biosimilars and biopharma markets significantly.

Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings - Passport to Wall Street

Kalshi is launching 13 biotech-focused prediction contracts that let traders bet $1 on FDA drug approvals and PDUFA dates, partnering with AppliedXL, drawing concern over insider-information incentives, while competing with Polymarket and drawing input from figures like Anne Wojcicki and CFTC officials who see potential patient-hedging benefits, with Kalshi vetting guardrails to avoid affecting trial outcomes.

Get Ready: US FDA’s Massive Review Queue Could Set Up Record-Breaking Year For Novel Approvals

The article reports that in mid-2026 the US FDA faces a large backlog of novel drug applications, signaling a potential record-breaking year for approvals as reviewers handle a surge in submissions in the latter half of 2026.

This GLP-1 Stock Could Double by 2030. Here's Why | The Motley Fool

Viking Therapeutics (VKTX) could double by 2030 if its lead GLP-1 candidate VK2735 delivers strong phase 3 results by 2028–2030 (ideally matching Zepbound), while progress with the oral VK2735 and VK3019, and market growth in GLP-1 therapies, support substantial commercial potential, but risks include trial failures, side effects, competition, and current valuation around $4.4 billion.

Lilly offers up to $3.8 billion for AtaiBeckley in bet on ‘God molecule’ found in toad venom

Eli Lilly agreed to acquire AtaiBeckley for $2.8 billion upfront plus up to $1 billion in contingent rights (potentially $3.8 billion total) to pursue a full development program around 5-MeO-DMT, led by BPL-003 (intranasal mebufotenin) for treatment-resistant depression, which has shown positive Phase 2b results and received FDA Breakthrough Therapy designation, with Phase 3 trials now underway and initial pivotal results expected in early 2029.